OP-770 / Oncopeptides - LARVOL DELTA

Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH (PRNewswire) - P3 | N=495 | OCEAN (NCT03151811) | Sponsor: Oncopeptides AB | "Oncopeptides AB...announces that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American Society of Hematology Meeting, ASH, in New Orleans, Louisiana, USA, on December 10-13. The clinical abstract evaluated patients with multiple myeloma who were refractory to prior alkylators in the phase 3 OCEAN study. Data shows that melflufen is a safe and effective therapy in patients who are alkylator refractory, regardless of whether they received a prior autologous stem cell transplant or not. The preclinical posters are based on the Company's proprietary technology platforms for Peptide Drug Conjugate, PDC, and for NK-cell engagers, 'Small Polypeptide based Killer Engagers', SPiKE and have been materialized through partnerships with leading research institutions in Finland, Norway, and Sweden."

P3 data • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology